Expertise in
19
conditions

Dr. David D. Dingli

Hematology
MN - Cancer Transplant
200 1st St SW, 
Rochester, MN 
Accepting New Patients
Offers Telehealth
28 Years of Experience
Expertise in
19
conditions
MN - Cancer Transplant
200 1st St SW, 
Rochester, MN 

Overview

David Dingli is a Hematologist practicing medicine in Rochester, Minnesota. He has been practicing medicine for over 28 years.

Dr. Dingli is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Graft.

He is actively involved in clinical research, co-authoring 441 peer reviewed articles and participating in 2 clinical trials. Dr. Dingli is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MN

Hospital Affiliations

Mayo Clinic Health System - Cannon Falls
Mayo Clinic Health System - Mankato
Mayo Clinic Health System In Red Wing
Mayo Clinic Health System - Albert Lea And Austin
Mayo Clinic Hospital Rochester

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

MN - Cancer Transplant
200 1st St SW, Rochester, MN 55905

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Biological
Study Drugs: JCARH125, JCARH125 + Anakinra
Study Phase: Phase 1/Phase 2
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

441 Total Publications

Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.
Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.
Journal: American journal of hematology
Published: May 30, 2026
Similar Doctors
Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

MN - Cancer Hematology

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-229-0068
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ayalew Tefferi is a Hematologist practicing medicine in Rochester, Minnesota. Dr. Tefferi is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasms (MPN), Splenectomy, and Bone Marrow Transplant. Dr. Tefferi is currently accepting new patients.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

MN - Cancer Hematology

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-229-0068
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Angela Dispenzieri is a Hematologist practicing medicine in Rochester, Minnesota. Dr. Dispenzieri is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Primary Amyloidosis, POEMS Syndrome, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Dispenzieri is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

MN - Cancer Hematology

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-229-0068
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Morie Gertz is a Hematologist practicing medicine in Rochester, Minnesota. Dr. Gertz is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Primary Amyloidosis, Multiple Myeloma, Waldenstrom Macroglobulinemia, Bone Marrow Transplant, and Tissue Biopsy. Dr. Gertz is currently accepting new patients.

Frequently Asked Questions about Dr. David D. Dingli

How do I make an appointment with Dr. David D. Dingli?

You can book an appointment with Dr. David D. Dingli by calling their office at 507-910-0296. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David D. Dingli a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David D. Dingli is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David D. Dingli specialize in?

While Dr. David D. Dingli is a Hematology, they have specific expertise in Multiple Myeloma, Primary Amyloidosis, and Smoldering Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. David D. Dingli participate in research or clinical trials?

Yes. Dr. David D. Dingli has published 441 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. David D. Dingli's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David D. Dingli accept my insurance?

Dr. David D. Dingli accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 507-910-0296 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dingli's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile